Replacement Heart Valves
Edwards CEO Mussallem hopes FDA to accelerate approvals of medical devices
(Reuters) – U.S. health regulators appear open to speeding up approvals of medical devices that currently often reach European markets three to five years ahead of being cleared in the United States, the chief executive officer of Edwards Lifesciences (NYSE:EW) said.
Edwards Lifesciences affirms guidance, ups stake in CardioKinetix, lures Medtronic exec
TAVI: Direct Flow Medical raises $32m, names 1st CCO
Direct Flow Medical said today that it landed a $32 million funding round for its replacement heart valve technology and tapped a 25-year medical device veteran, Chris Richardson, to lead its commercialization program.
Xeltis raises $34m for regenerative heart valve tech
TAVI: JenaValve adds $11m to Series C round
UPDATED Nov. 18, 2014, with a clarification from JenaValve.
JenaValve Technology yesterday reported adding nearly $17.3 million to a Series C funding round, bring the total raise to nearly $79.8 million.